The Endometriosis drugs in development market research report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Endometriosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Endometriosis and features dormant and discontinued products.
GlobalData tracks 66 drugs in development for Endometriosis by 55 companies/universities/institutes. The top development phase for Endometriosis is preclinical with 27 drugs in that stage. The Endometriosis pipeline has 61 drugs in development by companies and five by universities/ institutes. Some of the companies in the Endometriosis pipeline products market are: SLBST Pharma, Bayer and Kissei Pharmaceutical.
The key targets in the Endometriosis pipeline products market include Gonadotropin Releasing Hormone Receptor (GNRHR), Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR), and Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3).
The key mechanisms of action in the Endometriosis pipeline product include Gonadotropin Releasing Hormone Receptor (GNRHR) Agonist with eight drugs in Pre-Registration. The Endometriosis pipeline products include seven routes of administration with the top ROA being Oral and ten key molecule types in the Endometriosis pipeline products market including Small Molecule, and Synthetic Peptide.
Endometriosis overview
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility, and abnormal bleeding. Risk factors include age, uterine abnormalities, history of pelvic infection, and family history. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), birth control pills, and progestins.
For a complete picture of Endometriosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
